Skip to content
91 (11) 32911528 , 32911529 |solution@brawnbiotech.com
Brawn Biotech Ltd. Logo Brawn Biotech Ltd. Logo
  • Home
  • About Us
    • Company Profile
    • MOA
    • Board of Directors and Senior Management Personnel
    • Vision
    • Business Alliance
    • Operations
      • Domestic Operations
      • International Operations
  • Products
    • Products
  • Contact Us
  • Investors
    • Composition of Board of Directors
    • Shareholding Pattern
    • Policies
      • Policies
      • Code for Prohibition of Insider Trading Code
      • Familiarization Programme For Independent Directors
      • Terms and Conditions for Appointment of Independent Directors
    • Integrated Filing
    • Newspaper Publications
    • Notice of Information
      • Board Meeting
      • General Meeting
    • Annual Report
    • Results Outcome
    • ISR and Nomination form
      • Shareholders Form
    • RTA and Compliance
    • Shareholders Information
    • Unpaid Unclaimed Dividend Account
    • Investor Contacts
    • Stock Performance
      • Listing Information
      • Stock History
    • Shareholder’s Query
    • Closure Of Trading Window
    • FAQ
  • AGM Meetings
    • AGM Meeting 23-24
    • AGM Meetings 24-25
  • Blog
  • Home
  • About Us
    • Company Profile
    • MOA
    • Board of Directors and Senior Management Personnel
    • Vision
    • Business Alliance
    • Operations
      • Domestic Operations
      • International Operations
  • Products
    • Products
  • Contact Us
  • Investors
    • Composition of Board of Directors
    • Shareholding Pattern
    • Policies
      • Policies
      • Code for Prohibition of Insider Trading Code
      • Familiarization Programme For Independent Directors
      • Terms and Conditions for Appointment of Independent Directors
    • Integrated Filing
    • Newspaper Publications
    • Notice of Information
      • Board Meeting
      • General Meeting
    • Annual Report
    • Results Outcome
    • ISR and Nomination form
      • Shareholders Form
    • RTA and Compliance
    • Shareholders Information
    • Unpaid Unclaimed Dividend Account
    • Investor Contacts
    • Stock Performance
      • Listing Information
      • Stock History
    • Shareholder’s Query
    • Closure Of Trading Window
    • FAQ
  • AGM Meetings
    • AGM Meeting 23-24
    • AGM Meetings 24-25
  • Blog

Results Outcome

Home/Results Outcome
Results OutcomeBrawnBiotech2026-02-14T15:42:45+05:30

2025-26

Outcome of 1st BM
Outcome of 2nd BM
Scrutinizer Report_2025
AGM_2025 Voting results
Outcome of 5th BM
Outcome of 6th BM

2024-25

Outcome of 1st BM
Outcome of 2nd BM
Scrutinizer Report_24
AGM_2024-Voting results

2023-24

Outcome of 1st BM
Outcome of 2nd BM
Outcome of 3rd BM
Outcome of 4th BM
Voting Results 2023
Scrutinzer-Report

2022-23

Outcomes of 5th BM_DSC
Outcome of 1st BM
Outcome of 2nd BM
Outcome of 3rd BM
Outcome of 4th BM
VR Scrutinizers Report
Voting-Result_2022

2021-22

Outcome of 1st BM
Outcome of 2nd BM
Proceedings-and-Outcome-of-AGM_2021
Voting-Result_2021
Scrutinizer-report_20-21
Sep_30_2021_Outcome
OUTCOME_DEC_2021

2020-21

Outcome of 1st BM
Outcome of 2nd BM
Outcome of 3rd BM
Outcome of 4th BM
Outcomes of AGM_2019-20
Scrutinizer Report_2019-20
Voting Results_2019-20

Important Links

  • About Us
  • FAQ
  • Products

Contact Us

  • Email
    solution@brawnbiotech.com
  • Phone
    011- 29815331

Address

Brawn Biotech Limited
C-64, Lajpat Nagar - 1, New Delhi,
Delhi - 110024

Web: https://brawnbiotech.com/

© Copyright | Brawn Biotech Ltd | All Rights Reserved
Facebook

IMPORTANT ANNOUNCEMENT

To,

The Shareholders/ Promoters,

 

Notice for another Special Window for Transfer of Physical Shares

SEBI vide its circular no. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30 January 2026 has decided to open another special window for a period of one year from 05 February 2026 to 04 February 2027, for transfer of physical shares, which were sold/purchased prior to 01 April 2019, including such transfer requests which were submitted earlier and were rejected or returned or not attended to due to deficiency in the documents/ process/or otherwise, in order to facilitate ease of investing for investors and to secure the rights of investors in the securities which were purchased by them. During this period, the securities so transferred shall be mandatorily credited to the transferee only in demat mode and shall be under lock-in for a period of one year from the date of registration of transfer. Such securities shall not be transferred/lien-marked/ pledged during the said lock-in period.

The concerned investors are requested to take advantage of this Special Window, which remains open until 04 February 2027, to submit the documents such as; (a) Original share certificate(s), (b) Transfer deed executed prior to 01 April 2019, (c) Proof of purchase by Transferee, as may be available, (d) KYC documents of the transferee (as per ISR forms), (e) Latest Client Master List (CML), not older than 2 months, of the demat account of the transferee, duly attested by Depository Participant, (f) Undertaking cum Indemnity, to the Company’s Registrar and Share Transfer Agent (RTA) at RCMC Share Registry Pvt Ltd, B-25/1, 1st Floor, Okhla Industrial Area, Phase-II, New Delhi-110020, India.

UPDATE KYC AND CONVERT PHYSICAL SHARES INTO DEMAT MODE

The Shareholders who are holding shares in Physical form are requested to update their KYC and also requested to convert their physical share Certificates in to dematerialized form (electronic Form). Further pursuant to SEBI Circular No. SEBI/Cir/ISD/3/2011 dated June 17, 2011 in order to promote dematerialization of securities, it is mandatory for the Company to achieve 100% of promoter's and promoter group's shareholding in dematerialized form, thereby they are requested to convert their holdings in dematerialized form on priority basis.

 

 Thanks

 Brawn Biotech Limited.

This will close in 0 seconds

Go to Top